 |
| Research article summary (published 9 Jun 2003): |
|
Free Full Text! See links below |
Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds.
Full Abstract
Although previous studies report cognitive improvement following atypical antipsychotic administration in schizophrenia (SC), few placebo-controlled within-subject studies with examination of confounds (symptom reduction, cooperation, learning, and outliers) have been reported. The present study examines the effects of atypicals and confounds upon cognition in SC. The hypothesis tested was that relative to placebo, atypicals as a general class of medication would elicit cognitive improvement in SC. In all, 19 patients with SC (15 males) completed the double-blind, counterbalanced, randomized within-subject study of the effects of atypical antipsychotics (risperidone, clozapine, olanzapine, or quetiapine) vs placebo administration upon cognitive performance in the domains of executive function, attention, memory, language, visual perception, and general intellect. Significant cognitive improvement during atypical antipsychotic administration relative to placebo withdrawal occurred in most cognitive domains with robust improvements in intelligence (p=0.001), memory (p=0.0009), and fluency (p <0.002) even after outliers and unmotivated performances were excluded. These findings suggest that relative to placebo withdrawal, atypicals improve cognitive performance in SC. However, this finding may not be specific to atypicals, since analogous studies of typicals have not been performed.
Learn Faster Today Improve your study skills
Author information
Author/s: Weickert, Thomas W (TW); Goldberg, Terry E (TE); Marenco, Stefano (S); Bigelow, Llewellyn B (LB); Egan, Michael F (MF); Weinberger, Daniel R (DR);
Affiliation: Clinical Brain Disorders Branch, National Institute of Mental Health/NIH, Building 10 Room 4N202, MSC 1379, Bethesda, MD 20892, USA. weickert(-atsign-)intra.nimh.nih.gov
Journal and publication information
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (Neuropsychopharmacology), published in United States. (Language: eng)
Reference: 2003-Aug; vol 28 (issue 8) : pp 1491-500
Dates: Created 2003/07/23; Completed 2003/09/12; Revised 2006/11/15;
PMID: 12799617, status: MEDLINE (last retrieval date: 11/6/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
Comments and Corrections
ErratumIn: Neuropsychopharmacology. 2003 Dec;28(12):2217.
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
This article has not been indexed for related articles as yet, however you can still use the live related article search links below.
See a large map of 100+ related articles.